A Single-center, Interventional Diagnostic Study With Minimal Risks and Constraints, Aimed at Longitudinally Evaluating Serum Antibody Levels in Patients With COVID-19 According to the Severity of Their Symptoms. (COVERT)

Bioaster

Status

Completed

Conditions

COVID-19

Treatments

Biological: blood sample

Study type

Interventional

Funder types

Other

Identifiers

NCT06862531

2020-A02008-31

Details and patient eligibility

About

The COVERT protocol was designed to assess, through a longitudinal analysis, the level of antibodies present in the serum of patients with COVID-19, the duration and the persistence of the humoral response in correlation with the severity of the disease.

Enrollment

40 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Age ≥18 years old,
Patient whose Covid-19 diagnosis has been confirmed by RT-PCR test (SARS-CoV-2 positive) from a nasopharyngeal swab/broncho alveolar lavage
Patient whose severity of Covid-19 required hospital treatment
Patient whose Covid-19 form is defined as moderate (stay in general ward) or severe (stay in ICU), based on the clinical evaluation conducted by the doctor
Patient agreeing to participate in the study and having signed the informed consent.

Exclusion criteria

Adult person subject to legal protection,
Pregnant, parturient or breastfeeding woman
Person not affiliated to a social security scheme or not beneficiary of such a scheme
Person subject to a safeguard measure
Person deprived of liberty by a judicial or administrative decision and woman hospitalized without consent under Articles L.3212-1 and 3213-1, which do not fall under Article L.1122-8 of the Public Health Code.